Evaluation of variation in coagulation among children with Mycoplasma pneumoniae pneumonia: a case-control study

Tianhua Li1, Haiying Yu1, Weina Hou2

  • 11 Department of Paediatrics, Weifang People's Hospital, Weifang City, Shandong Province, China.

Insights

Children with Mycoplasma pneumoniae pneumonia (MPP) show increased blood coagulation and thrombosis risk. Early management of these coagulation changes is crucial for better outcomes in pediatric patients.

Area of Science:

  • Pediatric Infectious Diseases
  • Hematology
  • Pulmonology

Background:

  • Mycoplasma pneumoniae pneumonia (MPP) can lead to acute organ embolism in children.
  • Coagulation changes associated with MPP in pediatric cases require further investigation.

Purpose of the Study:

  • To investigate alterations in blood coagulation parameters in children diagnosed with MPP.
  • To assess the potential link between MPP and an increased risk of thrombosis.

Main Methods:

  • A cohort of 185 children with MPP (cases) and 117 healthy children (controls) were enrolled.
  • Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), plasma fibrinogen (FIB), and D-dimer levels were measured.

Main Results:

  • Children with MPP exhibited significantly higher plasma FIB and D-dimer levels compared to controls.
  • PT and APTT were significantly shorter in children with MPP than in the control group.
  • No significant differences in coagulation parameters were observed between high and low IgM-titre groups.

Conclusions:

  • Pediatric patients with MPP demonstrate an elevated risk of blood coagulation and thrombosis.
  • Prompt consideration and management of coagulation abnormalities are recommended for children with MPP.